Janux Therapeutics (NASDAQ:JANX) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Janux Therapeutics (NASDAQ:JANX) posted its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13, FiscalAI reports. The business had revenue of $9.29 million during the quarter, compared to analysts’ expectations of $8.03 million.

Janux Therapeutics Stock Down 11.7%

NASDAQ:JANX traded down $2.12 during trading hours on Thursday, hitting $16.06. 893,121 shares of the stock traded hands, compared to its average volume of 755,955. The company has a market cap of $981.91 million, a price-to-earnings ratio of -9.79 and a beta of 2.44. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34. The stock has a 50 day moving average price of $17.52 and a 200 day moving average price of $15.39.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on JANX shares. Wolfe Research upgraded shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a research report on Monday, August 24th. HC Wainwright reiterated a “buy” rating on shares of Janux Therapeutics in a research note on Monday, October 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Friday, October 16th. Guggenheim reduced their price objective on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Finally, TD Cowen raised Janux Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.46.

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.